PharmaShots | Incisive News in 3 Shots

Subscribe Now

BRCA-Mutated

AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mutated Ovarian Cancer

AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mut...

September 18, 2020

AstraZeneca and MSD's Lynparza (olaparib) Receives EC's Approval for BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca and MSD's Lynparza (olaparib) Receives EC's Approval for BRCA-Mutated Metastatic Pancreatic Cancer

July 8, 2020

AstraZeneca's Lynparza (olaparib) Receives MHLW's Orphan Drug Designation for BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca's Lynparza (olaparib) Receives MHLW's Orphan Drug Designation for BRCA-Mutated Metastatic Pancreatic Cancer

March 19, 2020

AstraZeneca and Merck &Co's Lynparza Receive the US FDA's Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca and Merck &Co's Lynparza Receive the US FDA's Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastat...

December 30, 2019

Pfizer's Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

Pfizer's Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated Locally Advanced or Metastatic Bre...

June 24, 2019

AstraZeneca and MSD's Lynparza (olaparib) Receive European Commission's Approval as 1L Maintenance Treatment for BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and MSD's Lynparza (olaparib) Receive European Commission's Approval as 1L Maintenance Treatment for BRCA-Mutated Adva...

June 18, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us